Diabetic Peripheral Neuropathy Clinical Trial
— EA&DPNOfficial title:
Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy and Its Correlation With Nerve Conduction Changes
This is a controlled clinical trial with the aim to study the effects of electroacupuncture on neuropathic pain reduction, quality of life and changes in sensory and motor nerve conduction velocity in patients with type 2 diabetes mellitus, beneficiaries of the familiar medical centers 20, 40 and 41 of the Instituto Mexicano del Seguro Social, at north of Mexico City, in colaboration with the human acupuncture specialty of the Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional, Mexico.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients with type 2 diabetes. - Patients with clinical diabetic peripheral polyneuropathy. - Patients with electrophysiological diagnosis of diabetic peripheral polyneuropathy in its different types of classification. Exclusion Criteria: - Type 1 Diabetes or gestational diabetes. - Systemic autoimmune diseases. - Hematological disorders. - HIV diagnosis. - Cancer in treatment. - Pregnancy. - Other types of neurological disorders or neuropathies. - Intervention with acupuncture six months previously. - Patients with pacemarkers. |
Country | Name | City | State |
---|---|---|---|
Mexico | Medical research unit in biochemistry, UMAE "Dr. Bernardo Sepúlveda".Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. | Mexico City | Cuauhtémoc |
Lead Sponsor | Collaborator |
---|---|
Instituto Mexicano del Seguro Social | Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional, Escuela Superior de Medicina, Instituto Politécnico Nacional, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de Mexico, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de Mexico, Facultad de Medicina, UNAM, Instituto Nacional de Salud Publica, Mexico, National Polytechnic Institute, Mexico, Universidad Nacional Autonoma de Mexico |
Mexico,
Perez Hernandez MF, Calderon Vallejo A, Aguilar Castillo SJ, Gomez Jimenez DC, Rodriguez Guerrero E, Aguilar Morales F, Moreno Tovar MG, Zurita Munoz MA, Bautista Cortez AE, Calzada Mendoza CC, De Nova Ocampo MA, Ordonez Rodriguez JM, Gomez Esquivel ML, Garcia Mendez A, Flores Gil O, Macias Zaragoza VM, Cortes Moreno GY, Salinas Lara C, Velazquez Garcia G, Saldivar Ceron HI, Perez Navarro LM, Avila Jimenez L, Gomez Zamudio JH, Diaz Flores M, Cruz Lopez M, Ocharan Hernandez ME, Peralta Romero JJ. Electroacupuncture efficacy in diabetic polyneuropathy: Study protocol for a double-blinded randomized controlled multicenter clinical trial. BMC Complement Med Ther. 2024 Feb 15;24(1):90. doi: 10.1186/s12906-024-04375-8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Nerve Conduction Velocity | Measured by Nerve Conduction Velocity Study using the VIKING LIFE-SAVING EQUIPMENT, to determine Motor and Sensitive Nerve Conduction Velocity of common peroneal nerve, sural nerve, and tibial nerve.
Sensitive Nerve Conduction (SCV). Distance between the receiving point and the stimulus point. SCV normal values: Peroneal nerve = 41 m/s, tibial nerve = 44 m/s, sural nerve = 50 m/s. Motor Conduction Velocity (MCV). Distance between two points and the difference in incubation between them after superstimulation of the corresponding nerve branch. MCV normal values: Peroneal nerve = 41 m/s, tibial nerve = 44 m/s, sural nerve = 60 m/s. *Values below those stipulated above indicate that NCV has slowed down, and is abnomal. The investigators expect a diminishment of SCV and MCV in sham acupuncture group from the first cycle of intervention whereas electroacupuncture group remains unchanged or even increases SCV and MCV. |
Baseline evaluation, after the first and second cycle of intervention, respectively, and three months after the end of the intervention. | |
Secondary | Michigan Neuropathy Screening Instrument (MNSI). | It will be assessed with a lower extremity examination by a health professional of both feet in search of deformities, dry skin, calluses, infections, fissures and ulcers. Complemented with measurement of vibratory sensation, ankle reflexes, and Semmes-Weinstein monofilament test.
The investigators expect improvement in the physical aspect of the foot in the electroacupuncture group, while in the sham acupuncture group the complication progresses. |
Baseline evaluation, after the first and second cycle of intervention, respectively, and three months after the end of the intervention. | |
Secondary | Michigan Diabetic Neuropathy Score (MDNS) | Composed of three items where the sensory compromise is evaluated with the perception of vibration, 10 gr. monofilament and pin prick, in addition to the muscular strength of the toes, and the bicipital, tricipital, quadriceps and achilles muscle reflexes. The investigators expect a diminishment of MDNS score and clinical improvement in the electroacupuncture group and progression of clinical manifestations in the sham group. | Baseline evaluation, after the first and second cycle of intervention, respectively, and three months after the end of the intervention. | |
Secondary | Douleur Neuropathique en 4 Questions (DN-4) | A screening tool for neuropathic pain consisting of 10 interview questions (DN4-interview) and physical tests. A score greater than 4 points suggests neuropathic pain. The investigators expect decreased scores in the electroacupuncture group and increased or persistent scores in the sham group. | Baseline evaluation, after the first and second cycle of intervention, respectively, and three months after the end of the intervention. | |
Secondary | Numerical Pain Rating Scale (NRS) | Patients are only asked to circle the number between 0 and 10, 0 and 20 or 0 and 100 that best matches the intensity of their pain currently and in the last 7 days, where zero usually represents "no pain", while the upper limit represents "the worst pain of their life". The investigators expect diminishment of rating scale in electroacupuncture group and an increase in sham acupuncture group. | Baseline evaluation, after the first and second cycle of intervention, respectively, and three months after the end of the intervention. | |
Secondary | Quality life (SF-36) | It will be measured by The Short Form-36 Health Survey (SF-36) a measure of health status that consists of eight scaled scores (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health), which are the weighted sums of the questions in their section. The investigators expect quality life improvement in electroacupuncture group while in sham acupuncture group might worsen. | Baseline evaluation, after the first and second cycle of intervention, respectively, and three months after the end of the intervention. | |
Secondary | Oxidative Stress | Determined by quantifying the concentrations of the lipoperoxidation product Malondialdehyde (MDA). An increase of MDA is expected in the sham group, while in the electroacupuncture group it is expected to decrease. | Baseline evaluation, after the first and second cycle of intervention, respectively, and three months after the end of the intervention. | |
Secondary | Inflammatory response | Assessed by changes in serum concentrations of proinflammatory (IL-6, IL1ß, TNF-a and IL-18) and anti-inflammatory (IL-10) cytokines determined by quantitative ELISA by flow cytometry. The investigators expect increase of anti-inflammatory cytokine and decrease of proinflammatory cytokines in the electroacupuncture group, while in the sham group this is inversely presented. | Baseline evaluation, after the first and second cycle of intervention, respectively, and three months after the end of the intervention. | |
Secondary | Genetic expression | mRNA expression of 5-HT1AR, Neurokinin 1, a-adrenoreceptors, NGF (Nerve growth factor), CX3CR1, GAP-43 (Growth associated protein 43) and Neurotrophin (NT3), (Chemoline receptor 1) genes quantified by real-time PCR. The investigators expect an increase in gene expression in patients with electroacupuncture while in sham patients it is decreased or even unchanged. | Baseline evaluation, after the first and second cycle of intervention, respectively, and three months after the end of the intervention. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04638556 -
Effect of Circulating lncRNAs on Type 2 Diabetic Peripheral Neuropathy
|
||
Completed |
NCT05580705 -
Effects of Vibration Therapy in Addition to Routine Physical Therapy in Patients With Diabetic Neuropathy
|
N/A | |
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT00835757 -
Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT00553592 -
Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes
|
Phase 2 | |
Recruiting |
NCT05863793 -
Clinical Study of Acupuncture in the Treatment of Diabetic Peripheral Neuropathy
|
N/A | |
Withdrawn |
NCT05041816 -
Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT06074562 -
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
|
Phase 2 | |
Recruiting |
NCT04457531 -
LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy
|
Early Phase 1 | |
Completed |
NCT02947828 -
Polyneuropathy in Diabetes Mellitus Type 2
|
||
Completed |
NCT02056431 -
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01681290 -
Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT01474772 -
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)
|
Phase 3 | |
Completed |
NCT01086150 -
Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT03447756 -
Titration Study of ABX-1431
|
Phase 1 | |
Completed |
NCT04688671 -
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
|
Phase 2 | |
Completed |
NCT04984044 -
Effect of Vitamin D in Patients With Diabetic Peripheral Neuropathy to Alleviate Pain and Improvement of Symptoms
|
N/A | |
Completed |
NCT06130917 -
Effects of Multisystem Exercise on Balance, Postural Stability, Mobility and Pain in Patients With DPN.
|
N/A | |
Completed |
NCT01496365 -
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
|
Phase 2 |